Emergent BioSolutions Announces Dr. Stephen Lockhart Joins Company to Lead Commercial Product Development Subsidiary
mergent BioSolutions Inc. (NYSE: EBS) announced today that Dr. Stephen Lockhart has been appointed President, Emergent Product Development UK....
Emergent BioSolutions Gains Rights To VaxImmune(TM) From Coley Pharmaceutical Group to Expand Its Anthrax Franchise
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a license agreement with Coley Pharmaceutical Group, Inc. (Nasdaq:COLY) for the use of Coley's proprietary VaxImmune(TM)...
Emergent BioSolutions’ Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study
mergent BioSolutions Inc. (NYSE:EBS) announced today that preliminary results from a recently completed, randomized, placebo-controlled Phase II clinical study demonstrated that its single-dose,...
Emergent BioSolutions Announces the Appointment of Denise Landry as Senior Vice President, Quality
Emergent BioSolutions Inc. (NYSE: EBS) announced today that Ms. Denise Landry has joined the company as Senior Vice President, Quality with responsibility for managing and overseeing all Quality...
Emergent BioSolutions to Present at BIO InvestorForum 2007
Emergent BioSolutions Inc. (NYSE:EBS), announced today that it will present at the BIO InvestorForum on October 10, 2007 at 11:45 am Pacific Time at The Palace Hotel, San Francisco. Company...
Emergent BioSolutions Completes First Delivery of BioThrax(R) (Anthrax Vaccine Adsorbed) to The Department of Health and Human Services under New Contract
Emergent BioSolutions Inc. (NYSE:EBS), announced today that on September 28, 2007 it completed an initial delivery of doses of BioThrax(R) (Anthrax Vaccine Adsorbed) to the U.S. Department of Health...
Emergent BioSolutions Receives Development Contract from NIAID/BARDA to Fund Continued Development of Anthrax Therapeutic
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a development contract, valued at up to $9.5 million, in support of non-clinical and clinical studies of the company's...
Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services
Emergent BioSolutions Inc. (NYSE:EBS), announced today that it has signed a three year contract with the U.S. Department of Health and Human Services (HHS), with a total value of up to $448 million....
Emergent BioSolutions to Present at the Thomas Weisel Partners Healthcare Conference 2007
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company focused on developing, manufacturing and commercializing immunobiotics to prevent or treat disease, announced today that it will...
Emergent BioSolutions Reports Financial Results for Second Quarter 2007
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company focused on developing, manufacturing and commercializing immunobiotics to prevent or treat disease, announced today its financial...
Emergent BioSolutions to Release Second Quarter 2007 Financial Results on August 6, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company focused on developing, manufacturing and commercializing immunobiotics to prevent or treat disease, announced today that it will...
Emergent BioSolutions and HSBC Sign $30 Million Loan to Support Manufacturing Expansion Program
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that it has signed a $30 million loan agreement with HSBC Realty Credit Corporation (USA)...